Myriad Genetics Earns 2023 Great Place to Work Certification™
08 mai 2023 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, May 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has achieved the Great Place to Work®...
Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range
03 mai 2023 16h05 HE
|
Myriad Genetics, Inc.
Highlights: First quarter testing volumes grew 21% year-over-year and 10% sequentially, excluding contributions from the SneakPeek® Early Gender DNA Test.In the first quarter: Hereditary cancer...
Myriad Genetics to Participate in BofA Securities Healthcare Conference
02 mai 2023 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, May 02, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will be participating in the upcoming...
Myriad Genetics to Release First Quarter Financial Results on May 3, 2023
26 avr. 2023 16h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, April 26, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first quarter earnings conference call on...
77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey
19 avr. 2023 07h05 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, April 19, 2023 (GLOBE NEWSWIRE) -- From restricted or binge eating to excessive gambling to extreme social media use, 77% of Americans surveyed say they have used at least one...
Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification
18 avr. 2023 08h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, April 18, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Intermountain Precision Genomics, a service of...
Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program
12 avr. 2023 08h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, April 12, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and SimonMed® Imaging, one of the largest independent...
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
02 mars 2023 09h15 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, March 02, 2023 (GLOBE NEWSWIRE) -- Myriad Genetic, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Illumina Inc. (NASDAQ: ILMN), a global leader in DNA...
Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC
01 mars 2023 08h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, March 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the first evidence-based...
Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes
28 févr. 2023 16h05 HE
|
Myriad Genetics, Inc.
Highlights: Fourth quarter testing volumes grew 26% year-over-year, and 11% year-over-year excluding the contribution from the recent acquisition of Gateway Genomics and its SneakPeek® Early Gender...